SAMe and sexual functioning
- 1 August 2012
- journal article
- research article
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 27 (6) , 451-454
Abstract
Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73% of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction. We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI- nonresponders. Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo. In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication. CLINICAL TRIALS.GOV IDENTIFIER: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/NCT00093847.Keywords
This publication has 15 references indexed in Scilit:
- S-Adenosyl Methionine (SAMe) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical TrialAmerican Journal of Psychiatry, 2010
- Evidence for S-Adenosyl-L-Methionine (SAM-e) for the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2009
- Antidepressant Dose Reduction and the Risk of Relapse in Major Depressive DisorderPsychotherapy and Psychosomatics, 2007
- The Use of the Sexual Function Questionnaire as a Screening Tool for Women with Sexual DysfunctionThe Journal of Sexual Medicine, 2005
- S-Adenosylmethionine and 5-Methyltetrahydrofolate Are Associated With Endothelial Function After Controlling for Confounding by HomocysteineArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- S-Adenosyl-L-Methionine (SAMe) as an Adjunct for Resistant Major Depressive DisorderJournal of Clinical Psychopharmacology, 2004
- Treatment of Antidepressant-Associated Sexual Dysfunction With SildenafilJAMA, 2003
- Hydrogen Sulfide as a NeuromodulatorMolecular Neurobiology, 2002
- Initiation of and Adherence to Treatment for Mental DisordersMedical Care, 2000
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960